U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Clinical Review Report: Icosapent Ethyl (Vascepa): (HLS Therapeutics Inc.): Indication: Prevention of cardiovascular events in statin-treated patients [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Aug.

Cover of Clinical Review Report: Icosapent Ethyl (Vascepa)

Clinical Review Report: Icosapent Ethyl (Vascepa): (HLS Therapeutics Inc.): Indication: Prevention of cardiovascular events in statin-treated patients [Internet].

Show details

Appendix 4Definition of Statin Intensity

High-intensity statin therapyModerate-intensity statin therapyLow-intensity statin therapy
Daily dose lowers LDL-c, on average, by approximately > 50%Daily dose lowers LDL-c, on average, by approximately 30% to < 50%Daily dose lowers LDL-c, on average, by < 30%

Atorvastatin 40 mg to 80 mg daily

Rosuvastatin 20 mg to 40 mg daily

Atorvastatin 10 mg to 20 mg daily

Rosuvastatin 5 to 10 mg daily

Simvastatin 20 mg to 40 mg daily

Pravastatin 40 mg to 80 mg daily

Lovastatin 40 mg daily

Fluvastatin XL 80 mg daily

Fluvastatin 40 mg b.i.d.

Pitavastatin 2 mg to 4 mg daily

Simvastatin 10 mg daily

Pravastatin 10 mg to 20 mg daily

Lovastatin 20 mg daily

Fluvastatin 20 mg to 40 mg daily

Pitavastatin 1 mg daily

Source: 2013 American College of Cardiology/American Heart Association Blood Cholesterol Guideline.29

b.i.d. = twice daily; LDL-c = low-density lipoprotein cholesterol.

Copyright © 2020 Canadian Agency for Drugs and Technologies in Health.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK565994

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (1.0M)

Other titles in this collection

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...